June 22, 2026

BIO 2026 Opens San Diego: BioArctic-Lilly $800M BrainTransporter Pact, Novo Wegovy MASH Approved in Japan, TGA Australia Peptide Compliance Crackdown, USTR Germany Section 301, AGA POWER Framework Revision, Indena-Chemi PDC Partnership

BIO 2026 Day 1 brings BioArctic-Lilly $800M BrainTransporter pact; Wegovy MASH approved in Japan; TGA peptide crackdown; USTR Germany 301; AGA POWER revision.

6 stories · Covering industry, regulatory, research

Editor's Note

BIO 2026 opens in San Diego today, and BioArctic and Eli Lilly anchored the morning with BioArctic's fourth BrainTransporter partnership — $30M upfront plus up to $770M in milestones and tiered royalties — combining BioArctic's transferrin-receptor-mediated blood-brain-barrier delivery technology with an undisclosed Lilly neurodegeneration molecule, with Lilly assuming global development and commercialization. The Insilico Medicine + SK Biopharmaceuticals $2.5B AI neuroimmune collaboration we previewed Sunday landed formally as expected; we covered the financials yesterday. On the regulatory side, Novo Nordisk and Sumitomo Pharma's June 19 Japan MHLW approval makes Wegovy the first approved MASH treatment in Japan (based on ESSENCE Phase 3 Part 1), Australia's TGA escalated peptide-products enforcement to a formal compliance priority targeting BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295, the USTR launched a Section 301 investigation into Germany's persistent underpayment for innovative pharmaceuticals on June 18 with the public comment docket opening June 25, and the American Gastroenterological Association republished its POWER framework in Gastroenterology on June 19 to formalize a multidisciplinary obesity-care model integrating GLP-1 medications, endoscopic therapies, and bariatric surgery. Indena and Chemi closed a peptide-drug-conjugate manufacturing partnership reflecting the broader CDMO consolidation pattern.

Industry

BioArctic + Eli Lilly Sign BrainTransporter Neurodegeneration Collaboration — $30M Upfront, Up to $770M Milestones + Mid-Single-Digit Royalties — Lilly's Fourth Blood-Brain-Barrier Bet After Alzheimer's Programs

BioArctic (Nasdaq Stockholm: BIOA b) announced on June 22, 2026 a research and collaboration agreement with Eli Lilly combining BioArctic's proprietary BrainTransporter technology — transferrin-receptor-mediated active transport across the blood-brain barrier — with an undisclosed Lilly proprietary molecule in neurodegeneration. BioArctic receives $30M upfront, eligibility for milestone payments up to $770M (total potential value ~$800M), plus tiered mid-single-digit royalties on global net sales. BioArctic will generate the new drug candidate combining the technology with Lilly's molecule; Lilly assumes full global development and commercialization responsibility. This is BioArctic's fourth BrainTransporter partnership, after collaborations with Bristol Myers Squibb (Alzheimer's), AbbVie, and an undisclosed partner. The deal signals continued big-pharma demand for blood-brain-barrier delivery platforms as neurodegeneration competition intensifies post-leqembi.

#bioarctic #eli-lilly #braintransporter #blood-brain-barrier #neurodegeneration #transferrin-receptor #bio-2026

Regulatory

Japan MHLW Approves Novo Nordisk Wegovy for MASH (June 19, 2026) — First Approved MASH Treatment in Japan, Co-Promoted With Sumitomo Pharma, Based on ESSENCE Phase 3 Part 1 Data

Japan's Ministry of Health, Labour and Welfare granted Novo Nordisk a partial change approval of the manufacturing and marketing authorization for Wegovy (semaglutide) subcutaneous injection on June 19, 2026, adding an indication for metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis in patients with moderate to advanced fibrosis (stage F2 or F3). Wegovy is now the first approved MASH treatment in Japan. The approval is based on Part 1 of the global Phase 3 ESSENCE study where semaglutide 2.4 mg demonstrated statistically significant superiority to placebo on the co-primary endpoints of liver fibrosis improvement without worsening of MASH, and MASH resolution without worsening of fibrosis. Wegovy is co-promoted in Japan by Novo Nordisk Pharma and Sumitomo Pharma under the October 2025 co-promotion agreement. This is the second major MASH regulatory milestone for semaglutide after the FDA's August 2025 approval.

#novo-nordisk #wegovy #semaglutide #mash #japan #mhlw #sumitomo-pharma #essence-phase-3

Regulatory

Australia's TGA Designates Unapproved Peptides a Formal Compliance Priority — Targets BPC-157, GHK-Cu, TB-500, Retatrutide, CJC-1295 With Infringement Notices, Import Seizures, and Civil/Criminal Penalties

Australia's Therapeutic Goods Administration (TGA) escalated its peptide-products oversight to a formal compliance priority in a June 2026 media release, citing rising importation, expanding online advertising and supply, and hospitalisation data identifying serious adverse effects associated with unapproved peptides. Targeted products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295. The TGA emphasized that unapproved peptide products are not in the Australian Register of Therapeutic Goods and have not been evaluated for safety, quality, or efficacy. An eight-month operation involving TGA, the Australian Border Force, and Victoria Police seized about $2M worth of peptides, performance-enhancing drugs, and illicit steroids. Future compliance responses may include infringement notices, product seizures, import interventions, and civil or criminal penalties; advertising or promoting unapproved peptides through social media or influencer channels is likely to breach Australian therapeutic goods advertising laws. The escalation parallels the FDA's PCAC reclassification track and tightens the global regulatory squeeze on the gray-market peptide channel.

#tga #australia #peptide-compliance #unapproved-peptides #bpc-157 #gray-market #enforcement

Regulatory

USTR Launches Section 301 Investigation into Germany's Persistent Underpayment for Innovative Pharmaceutical Products (June 18, 2026) — 9% Confidential-Pricing Discount + Draft 2027 Mandatory Patented-Medicine Rebate in Scope

The Office of the U.S. Trade Representative initiated a Section 301 investigation into Germany's pricing practices for innovative pharmaceuticals on June 18, 2026, alleging that Germany's persistent underpayment for innovative pharmaceutical products is unreasonable or discriminatory and burdens or restricts U.S. commerce. The investigation focuses on Germany's 9% price discount tied to pricing confidentiality and on draft 2026 German legislation that would add a mandatory rebate on patented medicines starting in 2027. The USTR public comment docket opens June 25, with submissions due by August 10 and a hearing scheduled for September 22, 2026. The investigation extends the most-favored-nation drug-pricing pressure President Trump applied to Lilly and Novo Nordisk under the TrumpRx framework toward European pricing regimes; if USTR finds Germany's practices harm US commerce, retaliatory tariffs on German pharmaceutical exports are among the available remedies — a meaningful threat to GLP-1 supply chains given Bachem and Boehringer Ingelheim's German manufacturing footprint.

#ustr #section-301 #germany #drug-pricing #trade-policy #mfn-pricing #trumprx

Research

AGA Gastroenterology Republishes POWER Framework June 19, 2026 — Multidisciplinary Obesity-Care Model Integrating GLP-1 Medications, Endoscopic Therapies, and Bariatric Surgery as Complementary Tools

The American Gastroenterological Association published a commentary in its journal Gastroenterology on June 19, 2026 revisiting and updating the influential POWER (Practice Guide on Obesity and Weight Management, Education, and Resources) framework, originally introduced in 2017. The revised framework reflects developments since 2017: the arrival of highly effective GLP-1 weight-loss medications (semaglutide, tirzepatide, retatrutide), expanded endoscopic therapies (Fractyl Revita duodenal mucosal resurfacing, intragastric balloons, endoscopic sleeve gastroplasty), and broader use of bariatric surgery. The framework formalizes a multidisciplinary care model that treats medications, endoscopic procedures, and surgery as complementary rather than competing — and addresses the post-GLP-1 weight-regain question by positioning endoscopic 'gut reset' procedures as part of the standard treatment arsenal. The commentary frames the next era of obesity care as combining GLP-1 medications with personalized procedures and surgery for greater results.

#aga #power-framework #gastroenterology #obesity-care #multidisciplinary #endoscopic-therapy #bariatric-surgery

Industry

Indena and Chemi (Italfarmaco Group) Announce Peptide-Drug Conjugate Manufacturing Partnership — Chemi Supplies Peptides, Indena Conjugates Highly Potent Payload Molecules; Reflects PDC Sector's CDMO Specialist-Pairing Pattern

Indena and Chemi S.p.A. (Italfarmaco Group) announced a strategic partnership in June 2026 combining peptide chemistry and high-potency API (HPAPI) conjugation expertise to position both firms as development and manufacturing partners for biotech and pharmaceutical companies pursuing peptide-drug conjugates (PDCs). Under the agreement, Chemi supplies the peptide carrier molecules and Indena handles the conjugation with highly potent payload molecules. Neither company is developing proprietary PDC drugs; the partnership reflects the broader CDMO consolidation pattern as the PDC modality scales (six PDCs in Phase 3 trials and ~96 in development globally per the April 2026 ResearchAndMarkets report, with Lutathera as the only FDA-approved standalone PDC after Pepaxto's withdrawal and the Pepaxti EMA expansion application pending). The partnership lands alongside CordenPharma's AmbioPharm acquisition and the broader sector reshaping.

#indena #chemi #italfarmaco #peptide-drug-conjugate #pdc-manufacturing #hpapi #cdmo